Targeting protein kinases in cancer therapy

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 5, 2002, Pages 701-712

  Fabbro, Doriano ^a   García Echeverría, Carlos ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiogenesis; Antagonists; Antibodies; Antitumor; Cancer therapy; Cell cycle; Drugs; Leukemia; Receptor; Signal transduction inhibitors; Signaling pathways

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CANERTINIB; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLT3 LIGAND; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; MONOCLONAL ANTIBODY; PACLITAXEL; PELITINIB; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB; TAK 165; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG DESIGN; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LIVER DYSFUNCTION; MOLECULAR DYNAMICS; NONHUMAN; RASH; RECEPTOR BLOCKING; REVIEW; TUMOR VASCULARIZATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; CYTOPLASM; ENZYME INHIBITORS; GENE THERAPY; HUMANS; MEMBRANE PROTEINS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 0036771375     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. de Bree, F, Sorbera, LA, Fernandez R, Castañer J: Imatinib mesilate. Drugs Future (2001) 26(6):545-552.
2. Savage DG, Antman KH: Imatinib mesylate - A new oral targeted therapy. N Engl J Med (2002) 346(9):683-693. An excellent review on the clinical efficacy of imatinib and the generation of resistance to this drug.
3. Druker BJ: STI571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol Med (2002) 8(4):S14-S18. A review on the clinical efficacy of imatinib and the generation of resistance to this drug.
4. Druker BJ: Perspectives on the development of a molecularly targeted agent. Cancer Cell (2002) 1(1):31-36.
5. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB: Potent and selective inhibitors of the ABL-kinase: Phenylaminopyrimidine (PAP) derivatives. Bioorg Med Chem Lett (1997) 7(2):187-192.
6. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 2(5):561-566.
7. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 56(1):100-104.
8. Griffin JD: Resistance to targeted therapy in leukaemia. Lancet (2002) 359(9305):458-459.
9. Gorre ME, Sawyers CL: Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol (2002) 9(4):303-307.
10. von Bubnoff N, Schneller F, Peschel C, Duyster J: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet (2002) 359(9305):487-491. Describes the detection of additional mutations in the catalytic domain of Bcr-Abl in patients treated with imatinib.
11. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293(5531):876-880. The first demonstration of the generation of resistance in patients treated with imatinib.
12. Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon F-X: Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 293(5538):2163a.
13. Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, Cross NC, Linkesch W, Druker BJ, Hehlmann R: Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 293(5538):2163a.
14. Gambacorti-Passerini C, Comeo G, D'lncalci M: Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 293(5538):2163a.
15. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science (2000) 289(5486):1938-1942. Describes the first crystal structure of an imatinib analog bound to the mouse Abl, demonstrating its unexpected binding mode.
16. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H et al: Protein kinases as targets for anti-cancer agents: From inhibitors to useful drugs. Pharmacol Ther (2000) 93(2-3):79-98.
17. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood (2000) 96(3):925-932.
18. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA: Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol (2000) 156(3):791-795.
19. Hirota S, lsozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (1998) 279(5350):577-580.
20. Heinrich MC, Blanke CD, Druker BJ, Codess CL: Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol (2002) 20(6):1692-1703. A comprehensive review on the molecular aspects of Kit activation, mutations, disease association and potential treatment modalities.
21. Blanke CD, von Mehren M, Joensuu H, Roberts PJ, Eisenberg B, Heinrich M, Druker B, Tuveson D, Dimtrijevic S, Silberman SL, Demitri GD: Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing c-Kit (CD117). 37th ASCO Meeting, San Francisco, CA, USA (2001) 20:Abs 1.
22. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 346(9):645-652.
23. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet (2001) 358(9291):1421-1423. Describes clinical efficacy data on imatinib in the treatment of GISTs.
24. Renhowe PA: Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy - clinical progress. Curr Opin Drug Discovery Dev (2002) 5(2):214-224. A recent review on receptor tyrosine kinases.
25. Adjei AA: Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy. Drugs Future (2001) 26(11):1087-1092.
26. Dumas J: Growth factor receptor kinase inhibitors: Recent progress and clinical impact. Curr Opin Drug Discovery Dev (2001) 4(4):378-389.
27. Morin MJ: From oncogene to drug: Development of small molecule tyrosine kinase inhibitors as anti-tumor and antiangiogenic agents. Oncogene (2000) 19(56):6574-6583. An interesting overview that includes development issues that, according to the author, have to be addressed in the development of tyrosine kinase inhibitors.
28. Herbst RS: ZD1839: Targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs (2002) 11(6):837-849. Summarizes the preclinical and clinical data on gefitinib.
29. Ciardiello F, Tortora G: Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs (2002) 11(6):755-768. A recent review on EGFR inhibitors.
30. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol (2002) 20(1):110-124.
31. Folkman J: Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg (1972) 175(3):409-416. A seminal paper in the field.
32. Shawver LK, Slamon D, Ulldch A: Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell (2002) 1(2):117-123. A concise review on the development of tyrosine kinase inhibitors.
33. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. AntiCancer Drug Des (2000) 15(1):29-41.
34. Pharmacia drops lead anti-angiogenesis product. Scrip (2002) February 13 (2720):23.
35. Hartman GD, Fraley ME, Bilodeau MT: Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents. Expert Opin Investig Drugs (2002) 11(6):737-745. A recent review on inhibitors of the VEGFR system.
36. Fabbro D, Manley PW: SU-6668. SUGEN. Curr Opin Investig Drugs (2001) 2(8):1142-1148.
37. Mendel DB, Laird AD, Xin X, Abrams TJ, Li G, Schreck RE, Carver J, Louie SG, Ngai TJ, Lee LB, Nannini MA et al: In vivo anti-tumor and mechanism of action studies of SU11248, a potent and selective inhibitor of the VEGF and PDGF receptors. 93rd AACR Meeting, San Francisco, CA, USA (2002):Abs 5349.
38. Abrams TJ, Lee LB, Murray LJ, Mendel DB, Cherrington JM: Inhibition of Kit-positive SCLC growth by SU11248, a novel tyrosine kinase inhibitor. 93rd AACR Meeting, San Francisco, CA, USA (2002):Abs 1669.
39. Bold G, Frei J, Furet P, Manley PW, Bruggen J, Cozens R, Ferrari S, Hofmann F, Martiny-Baron G, Mestan J, Meyer T, Wood JM: CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and bFGF-induced angiogenesis. Drugs Future (2002) 27(1):43-55.
40. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induce responses and tumor growth after oral administration. Cancer Res (2000) 60(8):2178-2189.
41. Thomas A, Morgon B, Drevs J, Jivan A, Buchert M, Horsfield M, Hennig J, Mross K, Henry A, Ball H, Peng B et al: Phamacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase 1 studies of the VEGFR inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. 37th ASCO Meeting, San Francisco, CA, USA (2001) 20:Abs 279.
42. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Pie PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO: Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem (2002) 45(6):1300-1312.
43. Rugged BA, Singh J, Hudkins R, Gingrich D, Angeles T, Robinson C, Chang H, Hunter K, Dobrzanski P, Pritchard S, Vaught J, Dionne C: CEP-7055: An orally-active VEGF-R kinase inhibitor with potent anti-angiogenic activity and anti-tumor activity efficacy against tumor xenograft growth. 93rd AACR Meeting, San Francisco, CA, USA (2002):Abs 5347.
44. Karp DD, Tolcher A, Healey D, O'Leary JJ, Debono J, Huberman M, Caulkins J, Molpus K, Sutula K, Noe DA: Preliminary pharmacokinetic (PK) characteristics of an oral vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase inhibitor (TKI), CP-547,632 in patients with advanced solid tumors. 93rd AACR Meeting, San Francisco, CA, USA (2002):Abs 2753.
45. Wiesmann M, Hoon Lee S, Wernette-Hammond M-E, Lapointe G, Cheryl G, Nordahl L, Heise C, Auiri P, Renhowe P, Harrison S, Harris A: Characterization of potent tyrosine kinase inhibitors that modulate angiogenesis and proliferation of selected cancer cell lines. 93rd AACR Meeting, San Francisco, CA, USA (2002):Abs 4208.
46. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H et al: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 97(8):2434-2439. This paper shows the prevalence of the D835 mutation and its association with poor prognosis in AML.
47. Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, Onodera N, Watanabe A, Kikuta A, Tanaka A, Asami K, Sekine I et al: Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Childen's Cancer and Leukemia Study Group, Japan. Leukemia (1999) 13(1):38-43.
48. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D: A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 99(11):3885-3891.
49. Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT: Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Res (2002) 62(4):986-989.
50. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, Gilliland DG, Griffin, JD: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 1(5):433-443.
51. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T: PKC412 - A protein kinase inhibitor with a broad therapeutic potential. AntiCancer Drug Des (2000) 15(1):17-28. Describes the identification of midostaurin as an inhibitor of FLT2.
52. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D et al: CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell (2002) 1:421-432. Describes the in vitro and in vivo characterization of MLN-518 for the treatment of FLT3-internal tandem duplication-positive AML.
53. Sawyers CL: Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell (2002) 1(5):413-415.
54. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2002) 344(14):1038-1042.
55. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood (2002) 99(10):3530-3539. The first report on the clinical efficacy of imatinib in CML.
56. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG: FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine marrow transplant model. Blood (2002) 99(1):310-318. An animal model that closely mimics FLT3-driven AML.
57. Baselga J, Albanell J, Molina MA, Arribas J: Mechanism of action of trastuzumab and scientific update. Semin Oncol (2001) 28(5 Suppl 16):4-11.
58. Slamon D, Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol (2001) 28(1 Suppl 3):13-19.
59. Friedrich MJ: Cardiotoxicity concerns prompt data review in breast cancer trial. J Natl Cancer Inst (2002) 94(9):650-651. A report on the risk of cardiotoxicity in clinical trials with trastuzumab.
60. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2002) 344(11):783-792.
61. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK: Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature (2002) 416(6878):279-280.
62. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer (2002) 94(5):1593-1611.
63. de Bono JS, Rowinsky EK: The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med (2002) 8(4):S19-S26. A recent review on the current status of agents targeting the ErbB family of tyrosine kinase receptors.
64. Baselga J: The EGFR as a target for anticancer therapy focus on cetuximab. EurJ Cancer (2001) 37(Suppl 4):S16-S22.
65. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol (2001) 19(13):3234-3243.
66. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 18(4):904-914.
67. Lynch DH, Yang XD: Therapeutic potential of ABX-EGF: A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol (2002) 29(1 Suppl 4):47-50.
68. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol (2001) 38(1):17-23.
69. Wallace PK, Romet-Lemonne JL, Chokri M, Kasper LH, Fanger MW, Fadul CE: Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcγRI and the epidermal growth factor receptor. Cancer Immunol Immunother (2000) 49(9):493-503.
70. Rosen LS: Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control (2002) 9(2 Suppl):36-44. The different strategies for cancer treatment with VEGF inhibitors are discussed in this article.
71. Ferrara N, Gerber HP: The role of vascular endothelial growth factor in angiogenesis. Acta Haematol (2001) 106(4):148-156.
72. Asano M, Yukita A, Suzuki H: Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res (1999) 90(1):93-100.
73. Sledge G, Miller K, Novotny W, Gaudreault J, Ash M, Colbeigh M: A phase II trial of single-agent RhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. 37th Am Soc Clin Oncol Meeting, San Francisco, CA, USA (2000) 19:Abs 5c.
74. Bergsland EK, Fehrenbacher L, Novotny W, Holmgren E, Lieberman G, Kabbinavar F: Bevacizumab (BV) + chemotherapy (CT) may improve survival in metastatic colorectal cancer (MCRC) subjects with unfavorable prognostic indicators. 37th Am Soc Clin Oncol Meeting, San Francisco, CA, USA (2001) 20:Abs 2247.
75. Johnson DH, DeVore R, Kabbinavar F, Herbst R, Holmgren E, Novotny W: Carboplatin (C) + paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced nonsquamous lung cancer. 37th Am Soc Clin Oncol Meeting, San Francisco, CA, USA (2001) 20:Abs 1256.
76. Asano M, Yukita A, Matsumoto T, Hanatani M, Suzuki H: An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma (1998) 17(2):185-190.
77. Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, Nakamura S, Yukita A, Asano M, Suzuki H, Baba S: Antitumor and anti-metastatic effects of human-vascularendothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer (1998) 77(6):933-936.
78. Hunt S: Technology evaluation: IMC-IC11, ImClone Systems. Curr Opin Mol Ther (2001) 3(4):418-424.
79. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadbum A, Hyjek E, Gill M, Hicklin DJ et al: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest (2000) 106(4):511-521.
80. Tomioka D, Maehara N, Kuba K, Mizumoto K, Tanaka M, Matsumoto K, Nakamura T: Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma ceils by NK4 in an orthotopic mouse model. Cancer Res (2001) 61(20):7518-7524.
81. Parr C, Davies G, Nakamura T, Matsumoto K, Mason MD, Jiang WG: The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant. Biochem Biophys Res Commun (2001) 285(5):1330-1337.
82. Maehara N, Matsumoto K, Kuba K, Mizumoto K, Tanaka M, Nakamura T: NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br J Cancer (2001) 84(6):864-873.
83. Matsumoto K, Nakamura T: Hepatocyte growth factor and Met in tumour invasion-metastasis: From mechanisms to cancer prevention. In: Cancer Metastasis, Molecular and Cellular Mechanisms and Clinical Intervention, Volume 1: Biology and Treatment. Jiang WG, Mansel RE (Eds), Kluwer Academic Publishers, Dordrecht, the Netherlands (2000):143-193.
84. Blaskovich MA, Lin Q, Delarue FL, Sun J, Park HS, Coppola D, Hamilton AD, Sebti SM: Design of GFB-111, a plateletderived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nat Biotechnol (2000) 18(10):1065-1070. Describes an interesting synthetic approach to block receptor autophosphorylation.
85. Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol (2001) 2(1):21-32.
86. Meijer L, Damiens E: CDK inhibitors: Small molecular weight compounds. In: Tumor-Suppressing Viruses, Genes, and Drugs. Maruta H (Ed), Academic Press, San Diego, CA, USA (2002):145-167.
87. Fischer PM: Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr Opin Drug Discovery Dev (2001) 4(5):623-634.
88. Zhai S, Senderowicz AM, Sausville EA, Figg WD: Flavopiṅdol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother (2002) 36(5):905-911.
89. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X et al: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol (2001) 19(8):2319-2333.
90. García-Echeverría C, Jiang L, Ramsey TM, Sharma SK, Chen YNP: A new Antennapedia-derived vector for intracellular delivery of exogenous compounds. Bioorg Med Chem Lett (2001) 11(11):1363-1366.
91. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair K W, Kaelin Jr WG: Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA (1999) 96(8):4325-4329.
92. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL: Enhances sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA (2001) 98(18):10314-10319.
93. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P et al: An inhibitor of mTOR reduces neoplasia and normalizes p70 / S6 kinase activity in Pten +/- mice. Proc Natl Acad Sci USA (2001) 98(18):10320-10325.
94. Herrera R, Sebolt-Leopold JS: Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med (2002) 8(4):S27-S31. A review on the Ras/Raf/MEK pathway and its modulation by inhibitors.
95. Kolch W: Ras/Raf signalling and emerging pharmacotherapeutic targets. Expert Opin Pharmacother (2002) 3(6):709-718. A review on the different approaches to target the Ras-RafMek-ERK path way.
96. Lyons JF, Wilhelm S, Hibner B, Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer (2001) 8(3):219-225. The discovery program based on inhibition of Raf kinase activity is outlined in this paper.
97. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 5(7):810-816.A study that demonstrates that suppression of MEK activity with PD-184352 can exert an antiproliferative effect on tumor cells.